Tango Therapeutics, Inc.
NASDAQ:TNGX
2.95 (USD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Revenue
| 36.527 | 24.86 | 37.042 | 7.656 | 24.649 |
| Cost of Revenue
| 2.415 | 4.028 | 1.966 | 1.625 | 32.274 |
| Gross Profit
| 34.112 | 20.832 | 35.076 | 6.031 | -7.625 |
| Gross Profit Ratio
| 0.934 | 0.838 | 0.947 | 0.788 | -0.309 |
| Reseach & Development Expenses
| 115.198 | 105.906 | 77.636 | 49.991 | 32.274 |
| General & Administrative Expenses
| 35.502 | 30.025 | 17.596 | 9.865 | 7.537 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 35.502 | 30.025 | 17.596 | 9.865 | 7.537 |
| Other Expenses
| 5.944 | 2.949 | 0.247 | 0.12 | 0 |
| Operating Expenses
| 150.7 | 135.931 | 95.232 | 59.856 | 7.154 |
| Operating Income
| -114.173 | -111.071 | -58.19 | -52.2 | -15.162 |
| Operating Income Ratio
| -3.126 | -4.468 | -1.571 | -6.818 | -0.615 |
| Total Other Income Expenses Net
| 5.944 | 2.949 | 0.247 | 0.228 | 1.067 |
| Income Before Tax
| -101.61 | -108.122 | -57.943 | -51.972 | -14.095 |
| Income Before Tax Ratio
| -2.782 | -4.349 | -1.564 | -6.788 | -0.572 |
| Income Tax Expense
| 0.134 | 0.054 | 0.292 | -0.108 | 0 |
| Net Income
| -101.744 | -108.176 | -58.235 | -51.864 | -14.095 |
| Net Income Ratio
| -2.785 | -4.351 | -1.572 | -6.774 | -0.572 |
| EPS
| -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| EPS Diluted
| -1.08 | -1.23 | -0.94 | -1.62 | -1.57 |
| EBITDA
| -111.758 | -111.071 | -58.19 | -51.482 | -14.519 |
| EBITDA Ratio
| -3.06 | -4.468 | -1.571 | -6.724 | -0.589 |